Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) | Zendy

Keith T. Flaherty | Zendy; Robert J. Gray | Zendy; Alice Chen | Zendy; Shuli Li | Zendy; Lisa M. McShane | Zendy; David R. Patton | Zendy; Stanley R. Hamilton | Zendy; P. Mickey Williams | Zendy; A. John Iafrate | Zendy; Jeffrey Sklar | Zendy; Edith P. Mitchell | Zendy; Lyndsay N. Harris | Zendy; Naoko Takebe | Zendy; David Sims | Zendy; Brent Coffey | Zendy; Tony Fu | Zendy; Mark J. Routbort | Zendy; James A. Zwiebel | Zendy; Larry Rubinstein | Zendy; Richard F. Little | Zendy; Carlos L. Arteaga | Zendy; Robert L. Comis | Zendy; Jeffrey S. Abrams | Zendy; Peter J. O’Dwyer | Zendy; Barbara A. Conley | Zendy

Open Access

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

Author(s) -

Keith T. Flaherty,

Robert J. Gray,

Alice Chen,

Shuli Li,

Lisa M. McShane,

David R. Patton,

Stanley R. Hamilton,

P. Mickey Williams,

A. John Iafrate,

Jeffrey Sklar,

Edith P. Mitchell,

Lyndsay N. Harris,

Naoko Takebe,

David Sims,

Brent Coffey,

Tony Fu,

Mark J. Routbort,

James A. Zwiebel,

Larry Rubinstein,

Richard F. Little,

Carlos L. Arteaga,

Robert L. Comis,

Jeffrey S. Abrams,

Peter J. O’Dwyer,

Barbara A. Conley

Publication year - 2020

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.19.03010

Subject(s) - medicine , cancer , clinical trial , cancer therapy , oncology , targeted therapy

Therapeutically actionable molecular alterations are widely distributed across cancer types. The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial was designed to evaluate targeted therapy antitumor activity in underexplored cancer types. Tumor biopsy specimens were analyzed centrally with next-generation sequencing (NGS) in a master screening protocol. Patients with a tumor molecular alteration addressed by a targeted treatment lacking established efficacy in that tumor type were assigned to 1 of 30 treatments in parallel, single-arm, phase II subprotocols.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research